-
Shining on Major News: Cooper-Standard Holdings Inc. (NYSE:CPS), Achillion Pharmaceuticals (NASDAQ:ACHN), Boston Scientific Corporation (NYSE:BSX), Interval Leisure Group (NASDAQ:IILG), Virtusa (NASDAQ:VRTU)
On Friday shares of Cooper-Standard Holdings Inc. (NYSE:CPS) closed at $63.80. Company’s sales growth for last 5 years was 10.80%. On May 07, Cooper-Standard Holdings Inc. (NYSE:CPS) reported net income of $21.0 million, or $1.15 per diluted share, and adjusted EBITDA of $80.8 million for the first quarter of 2015. These results compare to net […]
-
Top News: Oi SA (ADR) (NYSE:OIBR), Achillion Pharmaceuticals (NASDAQ:ACHN), BancorpSouth (NYSE:BXS), Take-Two Interactive Software Inc. (NASDAQ:TTWO), Ikonics Corp. (NASDAQ:IKNX)
On Thursday shares of Oi SA (ADR) (NYSE:OIBR) closed at $1.86. Company’s sales growth for last 5 years was 19.70%. Oi SA (ADR) (NYSE:OIBR) delivered significantly better results in 1Q, 15 with improvement in virtually all trends. We are reiterating our guidance for 2015 (routine EBITDA of R$ 7.0 to 7.4 billion and OCF improvement […]
-
Stocks in Focus: Vale S.A. (NYSE:VALE), American International Group (NYSE:AIG), Tesoro Logistics LP (NYSE:TLLP), Achillion Pharmaceuticals (NASDAQ:ACHN), NewBridge Bancorp (NASDAQ:NBBC)
On Wednesday shares of Vale S.A. (NYSE:VALE) closed at $8.19. Company’s sales growth for last 5 years was 10.00% and EPS growth for next 5 years is recorded as 0.01%. Vale S.A. (NYSE:VALE) said it could reduce forecasted iron ore production by up to 30 million tonnes over the next two years, as the miner […]
-
Shining on Major News: Achillion Pharmaceuticals (NASDAQ:ACHN), Johnson & Johnson (NYSE:JNJ), NF Energy Saving (NASDAQ:NFEC), International Business Machines (NYSE:IBM), ICF International (NASDAQ:ICFI)
On Monday shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) closed at $9.41. Company’s EPS growth for next 5 years is recorded as 17.58%. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) on 25 April, presented two late breaker posters at the 50th Annual Meeting of the European Association for the Study of the Liver (EASL) during The International Liver Congress […]
-
Morning Buzz: Achillion Pharmaceuticals (NASDAQ:ACHN), Ericsson (NASDAQ:ERIC), Alcatel Lucent SA (ADR) (NYSE:ALU), Pfizer Inc. (NYSE:PFE), Carriage Services Inc. (NYSE:CSV)
On Thursday shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) closed at $10.19. Company’s EPS growth for next 5 years is recorded as 17.58%. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) carries Zacks Rank #4 (Sell). On last trading day Ericsson (NASDAQ:ERIC) moved up 0.08% to close at $12.56. Its volatility for the week is 1.19% while volatility for the […]
-
Whats Hot Today: ZIOPHARM Oncology (NASDAQ:ZIOP), Achillion Pharmaceuticals (NASDAQ:ACHN), Aehr Test Systems (NASDAQ:AEHR), Kona Grill Inc. (NASDAQ:KONA), Marathon Petroleum (NYSE:MPC)
On Wednesday shares of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) closed at $11.05. Zacks reaffirmed their hold rating on shares of ZIOPHARM Oncology (NASDAQ:ZIOP) in a report issued on Sunday. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) in last trading activity moved down -3.69% to close at $10.17. Company weekly performance is -11.18% while its quarterly performance stands at -34.34%. […]
-
Best Stocks: BioTime (NYSEMKT:BTX), Achillion Pharmaceuticals (NASDAQ:ACHN), Teleflex Incorporated (NYSE:TFX), Foresight Energy, LP (NYSE:FELP), General Motors Company (NYSE:GM)
On Tuesday shares of BioTime, Inc. (NYSEMKT:BTX) closed at $5.46. Company’s sales growth for last 5 years was 22.30%. BioTime, Inc. (NYSEMKT:BTX) and its subsidiary OncoCyte Corporation on 20 March 2015, announced the online availability of abstracts providing human clinical data highlighting the potential of PanC-Dx™, OncoCyte’s class of non-invasive cancer diagnostics based on OncoCyte’s […]
-
Market Alert: Achillion Pharmaceuticals (NASDAQ:ACHN), Vivint Solar (NYSE:VSLR), LHC Group (NASDAQ:LHCG), Twitter Inc (NYSE:TWTR), Canadian Solar Inc. (NASDAQ:CSIQ)
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced Thursday that it will begin clinical trials with both drugs for Hepatitis-C patients some time in the first half of 2015. These trials will last between six weeks to three months, with results expected in the second half of the year. On Monday shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) closed […]